Preclinical study in multiple myeloma models revealed that FT suppressed the STAT3/5-DNA binding capacity while simultaneously inhibiting the activation of upstream kinases JAK1, JAK2 and Src [37]. This evidence concerns the gene STAT3 and plasma cell myeloma.